A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

Exclusion Criteria

• •Participation in another clinical trial within 3 months or receipt of any investigational medicinal product within 3 months prior to randomisation
• •Active malignant disease or malignant disease within the last 5 years with exception of fully treated local basal cell carcinoma or carcinoma in situ of cervix
• •Proliferative retinopathy judged by retina-photo within the last year - only with concomitant diabetes
• •Heart insufficiency, New York Heart Association (NYHA) class above 2
• •Adults with GHD with poorly controlled diabetes mellitus with a glycosylated haemoglobin (HbA1c) 64 mmol/mol (8.0%) and/or insulin treatment
• •Stable pituitary replacement therapy for less than 3 months